English abstract
Acute Myeloid leukemia (AML) is a multifaceted hematologic malignancy characterized by a
diverse range of prognoses. Using 16-plex TMT-LC/LC-MS/MS, we focused on a group of
proteins that showed upregulated expression in patients with peripheral blood diseases compared
to healthy controls. These proteins included HMGA1, HNRNPU, HMGN2, H1-2, RCC1, H3-2,
and H1-5. These proteins are implicated in essential biological processes such as Spliceosome
assembly, Nucleotide excision repair mechanism, and Ribosome biogenesis. In addition, it was
shown that ZNF207, SYNCRIP, HMGA1, HNRNPU, HMGN3, RPL26, COA6, COA5, and IER2
exhibited notable variations in expression levels when comparing peripheral blood disorders and
peripheral blood illnesses. This finding implies that these genes may have a potential use in the
diagnosis of AML. The proteins identified in this study were shown to be associated with the
KEGG pathways of Hematopoietic cell lineage, Spliceosome and ATP-dependent chromatin
remodeling.
Also, using ELISA, we examined the influence exerted by the initial levels of JAK/STAT, AKT,
TIM3, IDH1, and IDH2 expressions on the overall survival outcomes of patients diagnosed with
AML. The results of our study indicate that the protein expression levels examined do not have a
significant impact on the outcomes of patients with AML. However, it is important to note that
these findings may differ from past studies, highlighting the need for more investigation in this
area.
The overexpression of these proteins may be responsible for the possible improvement of
prognostic outcomes in patients with AML. To demonstrate a correlation between crucial
indicators and the prognosis of AML, next investigations must prioritize the inclusion of research
trials including significant participant cohorts. This approach will provide a more comprehensive
comprehension of the complicated nature of this illness and its prognostic implications.
